BACKGROUND: In-vitro studies have found that soy isoflavones can inhibit the activity of 17beta-hydroxysteroid dehydrogenase type I, a key enzyme in catalyzing estrone (E1), to the biologically more active estradiol (E2). OBJECTIVE: We hypothesized that soy food consumption may interact with polymorphisms in the 17beta-HSD1 gene in the development of endometrial cancer and evaluated this hypothesis in the Shanghai Endometrial Cancer Study. METHODS: Shanghai Endometrial Cancer Study is a population-based case-control study conducted among Chinese women in Shanghai. This study consisted of 1204 incident endometrial cancer cases diagnosed between 30 and 69 years of age and 1212 age frequency-matched community controls recruited from 1997 to 2003. Overall participation rates were 82.8% for cases and 74.4% for controls, whereas the DNA collection rates were 95.1% for cases and 94.2% for controls. RESULTS: We found that women carrying at least one A allele of the rs605059 polymorphism had a significant 18% reduction in risk of endometrial cancer compared with those without an A allele, and the association was primarily restricted to premenopausal women. The odds ratio (95% confidence interval) was 0.65 (0.47-0.88) for premenopausal women with at least one A allele versus those without an A allele. We also found that among premenopausal women soy isoflavone intake significantly interacted with the rs605059 genotype in relation to endometrial cancer and that the inverse association between soy isoflavone intake and endometrial cancer only appeared among those with at least one A allele of the rs605059 polymorphism. Among postmenopausal women, the association of soy isoflavone intake with endometrial cancer did not differ by 17beta-HSD1 genotypes. We did not find that the rs2676530 polymorphism was significantly associated with endometrial cancer risk. CONCLUSIONS: Our results suggest that soy consumption may interact with polymorphisms in the 17beta-HSD1 gene in relation to endometrial cancer risk. Further studies are warranted to confirm our results.
BACKGROUND: In-vitro studies have found that soy isoflavones can inhibit the activity of 17beta-hydroxysteroid dehydrogenase type I, a key enzyme in catalyzing estrone (E1), to the biologically more active estradiol (E2). OBJECTIVE: We hypothesized that soy food consumption may interact with polymorphisms in the 17beta-HSD1 gene in the development of endometrial cancer and evaluated this hypothesis in the Shanghai Endometrial Cancer Study. METHODS:Shanghai Endometrial Cancer Study is a population-based case-control study conducted among Chinese women in Shanghai. This study consisted of 1204 incident endometrial cancer cases diagnosed between 30 and 69 years of age and 1212 age frequency-matched community controls recruited from 1997 to 2003. Overall participation rates were 82.8% for cases and 74.4% for controls, whereas the DNA collection rates were 95.1% for cases and 94.2% for controls. RESULTS: We found that women carrying at least one A allele of the rs605059 polymorphism had a significant 18% reduction in risk of endometrial cancer compared with those without an A allele, and the association was primarily restricted to premenopausal women. The odds ratio (95% confidence interval) was 0.65 (0.47-0.88) for premenopausal women with at least one A allele versus those without an A allele. We also found that among premenopausal women soy isoflavone intake significantly interacted with the rs605059 genotype in relation to endometrial cancer and that the inverse association between soy isoflavone intake and endometrial cancer only appeared among those with at least one A allele of the rs605059 polymorphism. Among postmenopausal women, the association of soy isoflavone intake with endometrial cancer did not differ by 17beta-HSD1 genotypes. We did not find that the rs2676530 polymorphism was significantly associated with endometrial cancer risk. CONCLUSIONS: Our results suggest that soy consumption may interact with polymorphisms in the 17beta-HSD1 gene in relation to endometrial cancer risk. Further studies are warranted to confirm our results.
Authors: H Utsunomiya; T Suzuki; C Kaneko; J Takeyama; J Nakamura; K Kimura; M Yoshihama; N Harada; K Ito; R Konno; S Sato; K Okamura; H Sasano Journal: J Clin Endocrinol Metab Date: 2001-07 Impact factor: 5.958
Authors: A Mannermaa; H Peltoketo; R Winqvist; B A Ponder; H Kiviniemi; D F Easton; M Poutanen; V Isomaa; R Vihko Journal: Hum Genet Date: 1994-03 Impact factor: 4.132
Authors: Xiyan Mu; Xue Du; Kui Yao; Jitong Zhao; Ce Bian; Qiao Wang; Hongwei Ma; Tao Yi; Yang Wu; Xia Zhao Journal: Int J Clin Exp Pathol Date: 2015-06-01
Authors: Wang Hong Xu; Qi Dai; Yong Bing Xiang; Ji Rong Long; Zhi Xian Ruan; Jia Rong Cheng; Wei Zheng; Xiao Ou Shu Journal: Am J Epidemiol Date: 2007-09-07 Impact factor: 4.897
Authors: Hannah P Yang; Jesus Gonzalez Bosquet; Qizhai Li; Elizabeth A Platz; Louise A Brinton; Mark E Sherman; James V Lacey; Mia M Gaudet; Laurie A Burdette; Jonine D Figueroa; Julia G Ciampa; Jolanta Lissowska; Beata Peplonska; Stephen J Chanock; Montserrat Garcia-Closas Journal: Carcinogenesis Date: 2010-01-06 Impact factor: 4.944
Authors: Wang Hong Xu; Wei Zheng; Qiuyin Cai; Jia-Rong Cheng; Hui Cai; Yong-Bing Xiang; Xiao Ou Shu Journal: Nutr Cancer Date: 2008 Impact factor: 2.900
Authors: Joseph H Lee; Susan Gurney; Deborah Pang; Alexis Temkin; Naeun Park; Sarah C Janicki; Warren B Zigman; Wayne Silverman; Benjamin Tycko; Nicole Schupf Journal: Curr Gerontol Geriatr Res Date: 2012-03-04